INDICATION: Breast cancer
Cell culture studies suggest inhibiting NEK9 or MAP2K4 could help treat PI3K inhibitor-resistant triple-negative breast cancer (TNBC).
INDICATION: Breast cancer
Cell culture studies suggest inhibiting NEK9 or MAP2K4 could help treat PI3K inhibitor-resistant triple-negative breast cancer (TNBC).